Clinical Trials
106 trialsTargeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
Alterome Therapeutics, Inc.
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma
M.D. Anderson Cancer Center
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
GlaxoSmithKline
Pelvic Floor Dysfunction and Quality of Life in Uterine Cancer Survivors
M.D. Anderson Cancer Center
Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer
National Cancer Institute (NCI)
Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer
M.D. Anderson Cancer Center
TTBF
University of California, San Francisco
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Revolution Medicines, Inc.
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
National Cancer Institute (NCI)
MK-2870-001
Klus Pharma Inc.
FIERCE
University of Oklahoma
GEORGIA
Ohio State University Comprehensive Cancer Center
LPSvsLPT
Azienda USL Reggio Emilia - IRCCS
KEYNOTE-C93
Merck Sharp & Dohme LLC
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
National Cancer Institute (NCI)
PAM-II
University Medical Center Groningen
Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer
M.D. Anderson Cancer Center
ELEPHAS-02
Elephas
SISTER
University of Washington
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
University of California, San Francisco
DUoENDE
AstraZeneca
Infertility Survey Among Reproductive Age Women With Gynecological and Breast Cancer
M.D. Anderson Cancer Center
Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer
Danish Gynecological Cancer Group
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
EndomERA
Hoffmann-La Roche
PRESERVE-009
OncoC4, Inc.
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
USWM, LLC (dba US WorldMeds)
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
Seagen Inc.
TroFuse-005
Merck Sharp & Dohme LLC
GC-BIO
Institut Paoli-Calmettes
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
Agenus Inc.
Estrogen, Diet, Genetics and Endometrial Cancer
Memorial Sloan Kettering Cancer Center
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
Eisai Inc.
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
Atavistik Bio, Inc
Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
M.D. Anderson Cancer Center
Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer
Sun Yat-sen University
Abemaciclib and Letrozole to Treat Endometrial Cancer
GOG Foundation
Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention
M.D. Anderson Cancer Center
Longitudinal Evaluation of Women Undergoing Pelvic Surgery for the Treatment of Gynecologic Cancer
M.D. Anderson Cancer Center
ATARI
Institute of Cancer Research, United Kingdom
ONE TEAM
Duke University
First in Human Study of IMGN151 in Recurrent Gynaecological Cancers
AbbVie
PETRA
AstraZeneca
A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma
Yale University
Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Ohio State University Comprehensive Cancer Center
VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer
Mayo Clinic
IMPACTEndoAsia
Tata Memorial Hospital